GLP-1 Constipation: Causes and Next Steps

GLP-1 constipation is a listed effect of all four medicines, and each label's trial table reports it more often than placebo. Rates range from 3.1% on Ozempic 1 mg to 24% on Wegovy, in different trials. The labels give no fixed duration, so the practical points are knowing the warning signs and asking your prescriber what suits you. Severe pain, persistent vomiting or no stool or gas are signs to contact a doctor.

In short

• Ozempic's label reports constipation in 5.0% of people at 0.5 mg and 3.1% at 1 mg, against 1.5% on placebo, in type 2 diabetes trials.
• In separate weight-management trials of up to 68 and 72 weeks, Wegovy's label reports 24% against 11% on placebo, and Zepbound's reports 17% at 5 mg against 5%.
• All four labels list ileus and intestinal obstruction after approval. Separately, severe pain, persistent vomiting or no stool or gas are signs to contact a doctor.

How common is GLP-1 constipation in the label trials?

Each medicine's prescribing information lists constipation in its adverse reactions table, and every table shows a higher rate than placebo. The table below sets them side by side, with the severe gastrointestinal reaction rate beside it.

Sources are the Ozempic, Wegovy, Mounjaro and Zepbound labels. Ozempic and Mounjaro figures come from placebo-controlled type 2 diabetes trials. Mounjaro's pool is SURPASS-1 and SURPASS-5, with mean exposure of 36.6 weeks. Wegovy's trials enrolled adults with obesity or overweight for up to 68 weeks plus a 7-week follow-up. Zepbound's ran up to 72 weeks plus 4 weeks of follow-up.

The severe column covers all severe gastrointestinal reactions, not constipation alone. Because populations, doses and durations differ, the rows show each label's own results and do not rank one medicine above another.

Spain's CIMA data sheet for Ozempic lists constipation as frequent, meaning at least 1 in 100 but fewer than 1 in 10 people.

Why does a GLP-1 medication cause constipation?

GLP-1 medicines slow gastric emptying according to their labels, and whether that slowing causes constipation is not established. It is a plausible route, since food then moves through the gut more slowly. Eating and drinking less may add to it, because a smaller intake leaves less bulk and fluid in the bowel. That too is a possible contributor, not a proven cause.

A small case series using a wireless motility capsule found delayed motility in 90% of its patients, which is 9 of 10. That is an objective look at gut transit. It is not a constipation rate, and it is far too small to compare with the label tables above.

What is not known is how much comes from slower transit and how much from lower intake. The label tables count constipation but do not split it by cause.

Do the labels say when it starts and how long it lasts?

No. The labels report constipation over whole trials, with a mean exposure of 36.6 weeks in the Mounjaro pool and trials of up to 72 weeks in Zepbound's, and none states a start day, a peak or a typical duration. Those rates describe the whole trial, not a single week.

If you wonder whether a recent dose is still building up, two pages help. One covers how long it takes tirzepatide to reach steady state. Another gives a week-by-week decay table for how long semaglutide stays active. The free half-life calculator gives an estimate of how much medication is still active from your own doses. These explain timing of the medicine. They do not predict your bowels.

If constipation lasts longer than you expected, tell your prescriber.

Does a higher dose mean more constipation?

Not consistently: across the label tables, constipation rates do not climb steadily with dose. Zepbound's label shows 17% at 5 mg, 14% at 10 mg and 11% at 15 mg. Mounjaro's shows 6%, 6% and 7% at 5, 10 and 15 mg. Ozempic's shows 5.0% at 0.5 mg and 3.1% at 1 mg.

Severe gastrointestinal reactions in Zepbound's label do rise with dose, from 1.7% to 2.5% to 3.1%. Mounjaro's do not, at 1.3%, 0.4% and 1.2%.

The labels do not explain the pattern. Nothing here is a reason to change a dose. The prescriber decides.

What can you do about constipation on a GLP-1 medication?

The four labels give no advice for relieving constipation, so the safest step is to ask a prescriber or pharmacist what suits you. For readers choosing foods, USDA FoodData Central publishes fibre values, and the table shows fibre per 100 g, energy per 100 g, and fibre per 100 kcal.

The last column is derived: prunes 7.10 ÷ 240 × 100 = 3.0 g, chia 34.4 ÷ 486 × 100 = 7.1 g, pears 3.10 ÷ 57.0 × 100 = 5.4 g. These are published food composition values. They are not a personal target and do not show that any food relieves constipation.

• Ask your prescriber or pharmacist what suits you. Ask about fluids, fibre and any laxative. The labels give no such advice, and this guide gives no amounts or doses.
• Use the table only to compare foods. USDA FoodData Central describes composition, nothing more.
• Browse our food guide if it helps. What to eat on shot day lists USDA protein and fat figures for common foods.
• Tell your prescriber if it does not ease. Do not change, skip or stop a dose on your own.

When does constipation need a doctor or emergency care?

The four labels list ileus, intestinal obstruction and severe constipation including fecal impaction as post-marketing reports, and say a frequency cannot be reliably estimated. Contact your prescriber or emergency services promptly for any of these signs:

• Severe, persistent abdominal pain. The labels' pancreatitis warnings describe it, sometimes with vomiting.
• Persistent vomiting, or signs of dehydration. The labels warn that fluid loss can lead to kidney injury.
• Severe upper abdominal pain. The labels also carry gallbladder warnings.
• No stool and no gas. This is common clinical advice for possible ileus, not wording taken from the labels.

Do not wait to see whether these settle. Check the Zepbound label or your own medicine's label for the full warnings.

Can a symptom log show a pattern to share with a prescriber?

A day-by-day log can show whether constipation tracks with doses, water or food, and that is something to bring to a prescriber. Dose & Lose is a tracking app for iPhone and Android.

In the app, where side effects, water and protein intake can be logged day by day, you rate symptoms from 0 to 10 and see them over time next to your doses. It also tracks fibre and water goals. It does not diagnose or treat constipation, and it gives no dosing advice.

Frequently asked questions

Does Zepbound cause more constipation than Wegovy?

The labels cannot answer that, because the figures come from separate trials. Zepbound's label reports 17% at 5 mg against 5% on placebo over up to 72 weeks. Wegovy's reports 24% against 11% on placebo over up to 68 weeks. Populations and designs differ, so the choice belongs to you and your prescriber.

Can I take a laxative like MiraLAX while on Ozempic or Mounjaro?

Ask your prescriber or pharmacist first, because the four labels in this guide give no laxative advice and this guide gives no doses. The right choice depends on your health and other medicines. If constipation comes with severe pain, vomiting, or no stool or gas, seek care instead of treating it alone.

Is constipation a sign of ileus or bowel obstruction?

Constipation does not by itself mean ileus, but the labels list both. All four labels list ileus, intestinal obstruction and severe constipation with fecal impaction as post-marketing reports with no estimable frequency. Severe abdominal pain, vomiting, or no stool or gas are the signs to act on, so contact a doctor promptly.

Will constipation come back if my dose goes up?

The labels do not answer that directly. They report constipation over whole trials, not at each dose step, and the rates by dose group did not rise steadily. If it returns or worsens after a change, tell your prescriber, who decides about the dose.

Sources

• Ozempic prescribing information: rates, severe GI, post-marketing.
• Wegovy prescribing information: same sections.
• Mounjaro prescribing information: same sections.
• Zepbound prescribing information: same sections.
• CIMA Ozempic data sheet: EU frequency category.
• Wireless motility capsule case series: gut motility.
• USDA FoodData Central: prunes, chia, pears: fibre and energy.

Published by Petros IT Solutions SRL, byline Dose & Lose Editorial Team. Corrections: office@doseandlose.com.